PDAC
Clinical trials for PDAC explained in plain language.
Never miss a new study
Get alerted when new PDAC trials appear
Sign up with your email to follow new studies for PDAC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktails target Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs called RAS(ON) inhibitors, alone or with standard chemotherapy, in people with advanced colorectal or pancreatic cancer that has spread. About 1,130 adults will participate to see if these combinations are safe and can shrink t…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 03:42 UTC
-
New drug targets hard-to-treat cancers with KRAS G12V mutation
Disease control Recruiting nowThis study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…
Matched conditions: PDAC
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 03:42 UTC
-
New drug cocktail targets Hard-to-Treat KRASG12D cancers
Disease control Recruiting nowThis study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRASG12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or meta…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:32 UTC
-
New pill aims to keep pancreatic cancer at bay after surgery
Disease control Recruiting nowThis study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …
Matched conditions: PDAC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for hard-to-treat cancers: drug combo targets genetic weakness
Disease control Recruiting nowThis study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …
Matched conditions: PDAC
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New registry aims to catch deadly pancreatic cancer before it spreads
Knowledge-focused Recruiting nowThis study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…
Matched conditions: PDAC
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 18, 2026 12:12 UTC